0001209191-21-036095.txt : 20210526 0001209191-21-036095.hdr.sgml : 20210526 20210526201948 ACCESSION NUMBER: 0001209191-21-036095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210524 FILED AS OF DATE: 20210526 DATE AS OF CHANGE: 20210526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Perfetti Riccardo CENTRAL INDEX KEY: 0001775410 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 21968099 MAIL ADDRESS: STREET 1: C/O APPLIED THERAPEUTICS, INC. STREET 2: 340 MADISON AVENUE, 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10173 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9319 MAIL ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-24 0 0001697532 Applied Therapeutics Inc. APLT 0001775410 Perfetti Riccardo C/O APPLIED THERAPEUTICS, INC. 545 5TH AVENUE, SUITE 1400 NEW YORK NY 10017 0 1 0 0 Chief Medical Officer Common Stock 2021-05-24 4 M 0 1640 1.44 A 1640 D Common Stock 2021-05-24 4 S 0 1640 17.25 D 0 D Common Stock 2021-05-25 4 M 0 460 1.44 A 460 D Common Stock 2021-05-25 4 S 0 460 17.97 D 0 D Common Stock 2021-05-26 4 M 0 460 1.44 A 460 D Common Stock 2021-05-26 4 S 0 460 19.43 D 0 D Stock Option (Right to Buy) 1.44 2021-05-24 4 M 0 1640 0.00 D 2028-12-16 Common Stock 1640 171894 D Stock Option (Right to Buy) 1.44 2021-05-25 4 M 0 460 0.00 D 2028-12-16 Common Stock 460 171434 D Stock Option (Right to Buy) 1.44 2021-05-26 4 M 0 460 0.00 D 2028-12-16 Common Stock 460 170974 D Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised automatically pursuant to the reporting person's written trading plan previously entered into on September 16, 2020, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Automatic sales made pursuant to the reporting person's pre-existing written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.0000 to $17.5400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7300 to $18.5650 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.26 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Thirty-three percent (33%) of the shares subject to the option vested on August 27, 2018, and one twenty-fourth (1/24th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. /s/ Shoshana Shendelman, Attorney-in-Fact 2021-05-26